Patent classifications
C12N2502/081
METHOD OF IN VITRO CELLULAR ASSAY, CELL CIRCUIT BOARD, AND METHOD OF MANUFACTURING CELL CIRCUIT BOARD
A method of in vitro cellular assay includes measuring an electrical activity of at least two cell populations in a plurality of cell populations that are disposed to be spaced apart from each other and connected to each other via a neurite, in which at least one of the at least two cell populations for which the electrical activity is measured is a cell population including at least one kind of neural cell, and the at least two cell populations each exhibit different electrical activity properties at a point when the electrical activity is measured.
METHOD OF MANUFACTURING CELL SPHEROID USING BIOINK
Disclosed is a process of manufacturing cell spheroids using a bioink. More particularly, provided is a method of manufacturing a cell spheroid, the method including extruding a first bioink including an alginate; extruding a second bioink including cells into the extruded first bioink; adding a calcium chloride (CaCl2) solution to the alginate included in the first bioink; and dissolving the second bioink, present in the first bioink, in a cell culture medium to form a cell spheroid from the cells.
Microfluidic device for three dimensional and compartmentalized coculture of neuronal and muscle cells, with functional force readout
The present subject matter provides a microfluidic device that enables the precise and repeatable three dimensional and compartmentalized coculture of muscle cells and neuronal cells. Related apparatus, systems, techniques, and articles are also described.
METHODS AND DEVICES FOR PROMOTING NERVE GROWTH AND REGENERATION
In one aspect, methods of promoting asymmetric nerve growth and/or regeneration are described herein. In some embodiments, such a method comprises exposing a population of transected or severed nerves to a first molecular growth cue and to a second molecular growth cue. The population of transected nerves comprises one or more nerves of a first nerve type and one or more nerves of a second nerve type differing from the first nerve type. Additionally, the first molecular growth cue preferentially promotes growth of the first nerve type, as compared to the second nerve type. Similarly, the second molecular growth cue preferentially promotes growth of the second nerve type, as compared to the first nerve type. Moreover, the first molecular growth cue is spatially separated from the second molecular growth cue.
METHODS OF PRODUCING BIOENGINEERED NEURONAL ORGANOIDS (BENOS) AND USES THEREOF
The present invention relates to the field of in vitro 3D modeling of neural tissues, particularly of the brain. There is the need of developing cell culture models of neural tissue that reflect physiological aspects of neural tissue. The present invention provides methods of producing bioengineered neuronal organoids (BENOs) which form functional neuronal networks. The present invention also relates to uses and applications of the produced BENOs, e.g., in the fields of drug screening and personalized medicine.
DIAGNOSTIC METHODS FOR NEURAL DISORDERS
The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic butfor a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease
COMPOSITIONS AND METHODS FOR NEURALGENESIS
The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. mini-brains). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.
SUPPORTIVE NANOFIBRILLAR CELLULOSE SCAFFOLD FOR EXPANDING CELLS
The present invention is related to methods and materials for culturing expanding cells in a three-dimensional culture. The material comprises plant-derived anionic nanofibrillar cellulose, wherein the anionic nanofibrillar cellulose is in a form of hydrogel. The invention also provides methods for producing materials and compositions comprising plant-derived anionic nanofibrillar cellulose.
Diagnostic methods for neural disorders
The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.
STEM CELL MODEL OF APOE GENOTYPE AND Abeta42-DEPENDENT NEURODEGENERATION AND METHODS OF USING THE SAME
Provided is an isolated cell including a modified amyloid beta precursor protein (APP) gene. The modified APP gene encodes a secretory peptide, and the secretory peptide is Amyloid Beta.sub.1-40 (A.sub.1-40) or Amyloid Beta.sub.1-42 (A.sub.1-42). The isolated cell can additionally have a modified Apolipoprotein E (APOE) gene, and/or at least one marker. Also provided is an in vitro model including at least one population of cells having a modified APP gene encoding a secretory peptide such as A.sub.1-40 or A.sub.1-42. The population of cells is subjected to at least one differentiation protocol. Further provided is a method of screening treatments including contacting at least one population of cells disclosed herein with at least one agent and determining if the agent has an effect on phenotype. The agent is a drug, a salt, a mineral, an antibody, a humanized antibody, an enzyme, a protein, a peptide, a cell, a modified cell, a stem cell, a plant-based substance, a plant derivative, an antioxidant, or an antioxidant derivative.